Skip to main content


Page 206 of 208

  1. Cardiac rehabilitation programs (CRP) represent comprehensive interventions that are typically limited to four months. Following completion of CRP, it appears that risk factors and lifestyle behaviours may det...

    Authors: Scott A Lear, Andrew Ignaszewski, Wolfgang Linden, Anka Brozic, Marla Kiess, John J Spinelli, P Haydn Pritchard and Jiri J Frohlich
    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:9
  2. PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option.

    Authors: Ian Ford, Gerard Jan Blauw, Michael B Murphy, James Shepherd, Stuart M Cobbe, Edward LEM Bollen, Brendan M Buckley, J Wouter Jukema, Michael Hyland, Allan Gaw, A Margot Lagaay, Ivan J Perry, Peter Macfarlane, John Norrie, A Edo Meinders, Brian J Sweeney…
    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:8
  3. The "integrated safety report" of the drug registration files submitted to health authorities usually summarizes the rates of adverse events observed for a new drug, placebo or active control drugs by pooling ...

    Authors: Michel Lièvre, Michel Cucherat and Alain Leizorovicz
    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:6
  4. Antioxidant supplementation with vitamin E had no effect in the prevention of cardiovascular diseases (CVD) in three recent large, randomized clinical trials. In order to reassess critically the role of vitami...

    Authors: Chiara Chiabrando, Fausto Avanzini, Claudia Rivalta, Fabio Colombo, Roberto Fanelli, Gaetana Palumbo and Maria Carla Roncaglioni
    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:5
  5. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study was the first trial to assess whether statins might be of clinical benefit in those with recently unstable coronary disease. M...

    Authors: Herbert D Aronow
    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:3
  6. Although diabetes mellitus is predominantly a metabolic disorder, recent data suggest that it is as much a vascular disorder. Cardiovascular complications are the leading cause of death and disability in patie...

    Authors: Prakash C Deedwania
    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:2
  7. Overweight older adults are often counseled to lose weight, even though there is little evidence of excess mortality in that age group. Overweight and underweight may be more associated with health status than...

    Authors: Paula Diehr, Anne B Newman, Sharon A Jackson, Lewis Kuller and Neil Powe
    Citation: Current Controlled Trials in Cardiovascular Medicine 2002 3:1
  8. The treatment of patients with coronary artery disease continues to evolve; all three strategies – medical therapy, surgical revascularization, and percutaneous coronary intervention – have changed. Medical th...

    Authors: David R Holmes Jr
    Citation: Trials 2001 2:263
  9. This commentary has two purposes: to summarize the rationale, design and initial results of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial; and to provide a hist...

    Authors: Lawrence R Krakoff
    Citation: Trials 2001 2:254
  10. The identification of angiogenic growth factors, such as vascular endothelial growth factor and fibroblast growth factor, has fueled interest in using such factors to induce therapeutic angiogenesis. The resul...

    Authors: Yin-Shan Ng and Patricia A D'Amore
    Citation: Trials 2001 2:278
  11. The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascula...

    Authors: Lutgarde Thijs, Jan A Staessen, Sonia Beleva, Willem H Birkenhäger, Christopher J Bulpitt, Hilde Celis, Astrid E Fletcher, Rumjana Kermova, Gastone Leonetti, Tovio Laks, Stefan Mantov, Choudomir Nachev, Cinzia Sarti, Jaakko Tuomilehto and Robert H Fagard
    Citation: Trials 2001 2:298

Annual Journal Metrics

  • 2022 Citation Impact
    2.5 - 2-year Impact Factor
    2.5 - 5-year Impact Factor
    0.827 - SNIP (Source Normalized Impact per Paper)
    0.814 - SJR (SCImago Journal Rank)

    2023 Speed
    33 days submission to first editorial decision for all manuscripts (Median)
    129 days submission to accept (Median)

    2023 Usage 
    5,569 Altmetric mentions